Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1093 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape. Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 61, 60, 2, 114, 22 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 8, 18 and 6 molecules, respectively. Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology). - The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 9 Multiple Myeloma (Kahler Disease) Overview 10 Therapeutics Development 11 Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies 13 Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes 27 Multiple Myeloma (Kahler Disease) - Pipeline Products Glance 29 Multiple Myeloma (Kahler Disease) - Products under Development by Companies 33 Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes 57 Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development 60 Multiple Myeloma (Kahler Disease) - Therapeutics Assessment 208 Drug Profiles 261 Multiple Myeloma (Kahler Disease) - Dormant Projects 1022 Multiple Myeloma (Kahler Disease) - Discontinued Products 1048 Multiple Myeloma (Kahler Disease) - Product Development Milestones 1053 Appendix 1060
List of Tables
Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016 43 Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016 44 Number of Products under Development by Companies, H2 2016 46 Number of Products under Development by Companies, H2 2016 (Contd..1) 47 Number of Products under Development by Companies, H2 2016 (Contd..2) 48 Number of Products under Development by Companies, H2 2016 (Contd..3) 49 Number of Products under Development by Companies, H2 2016 (Contd..4) 50 Number of Products under Development by Companies, H2 2016 (Contd..5) 51 Number of Products under Development by Companies, H2 2016 (Contd..6) 52 Number of Products under Development by Companies, H2 2016 (Contd..7) 53 Number of Products under Development by Companies, H2 2016 (Contd..8) 54 Number of Products under Development by Companies, H2 2016 (Contd..9) 55 Number of Products under Development by Companies, H2 2016 (Contd..10) 56 Number of Products under Development by Companies, H2 2016 (Contd..11) 57 Number of Products under Development by Companies, H2 2016 (Contd..12) 58 Number of Products under Investigation by Universities/Institutes, H2 2016 59 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 60 Comparative Analysis by Late Stage Development, H2 2016 61 Comparative Analysis by Clinical Stage Development, H2 2016 62 Comparative Analysis by Early Stage Development, H2 2016 63 Comparative Analysis by Unknown Stage Development, H2 2016 64 Products under Development by Companies, H2 2016 65 Products under Development by Companies, H2 2016 (Contd..1) 66 Products under Development by Companies, H2 2016 (Contd..2) 67 Products under Development by Companies, H2 2016 (Contd..3) 68 Products under Development by Companies, H2 2016 (Contd..4) 69 Products under Development by Companies, H2 2016 (Contd..5) 70 Products under Development by Companies, H2 2016 (Contd..6) 71 Products under Development by Companies, H2 2016 (Contd..7) 72 Products under Development by Companies, H2 2016 (Contd..8) 73 Products under Development by Companies, H2 2016 (Contd..9) 74 Products under Development by Companies, H2 2016 (Contd..10) 75 Products under Development by Companies, H2 2016 (Contd..11) 76 Products under Development by Companies, H2 2016 (Contd..12) 77 Products under Development by Companies, H2 2016 (Contd..13) 78 Products under Development by Companies, H2 2016 (Contd..14) 79 Products under Development by Companies, H2 2016 (Contd..15) 80 Products under Development by Companies, H2 2016 (Contd..16) 81 Products under Development by Companies, H2 2016 (Contd..17) 82 Products under Development by Companies, H2 2016 (Contd..18) 83 Products under Development by Companies, H2 2016 (Contd..19) 84 Products under Development by Companies, H2 2016 (Contd..20) 85 Products under Development by Companies, H2 2016 (Contd..21) 86 Products under Development by Companies, H2 2016 (Contd..22) 87 Products under Development by Companies, H2 2016 (Contd..23) 88 Products under Investigation by Universities/Institutes, H2 2016 89 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 90 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 91 Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2016 92 Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H2 2016 93 Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2016 94 Multiple Myeloma (Kahler Disease) - Pipeline by Ablynx NV, H2 2016 95 Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H2 2016 96 Multiple Myeloma (Kahler Disease) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 97 Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 98 Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2016 99 Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 100 Multiple Myeloma (Kahler Disease) - Pipeline by ADC Therapeutics Sarl, H2 2016 101 Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2016 102 Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 103 Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2016 104 Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2016 105 Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H2 2016 106 Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H2 2016 107 Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2016 108 Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H2 2016 109 Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2016 110 Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H2 2016 111 Multiple Myeloma (Kahler Disease) - Pipeline by Arcarios BV, H2 2016 112 Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H2 2016 113 Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H2 2016 114 Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas Inc, H2 2016 115 Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H2 2016 116 Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H2 2016 117 Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 118 Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2016 119 Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2016 120 Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 121 Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2016 122 Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 123 Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 124 Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2016 125 Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H2 2016 126 Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2016 127 Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H2 2016 128 Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H2 2016 129 Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2016 130 Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2016 131 Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2016 132 Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2016 133 Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H2 2016 134 Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2016 135 Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2016 136 Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2016 137 Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 138 Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 139 Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences Inc, H2 2016 140 Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 141 Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2016 142 Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 143 Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 144 Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2016 145 Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H2 2016 146 Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 147 Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2016 148 Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 149 Multiple Myeloma (Kahler Disease) - Pipeline by Five Prime Therapeutics Inc, H2 2016 150 Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2016 151 Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2016 152 Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2016 153 Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 154 Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2016 155 Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2016 156 Multiple Myeloma (Kahler Disease) - Pipeline by GlyTR Therapeutics Inc, H2 2016 157 Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2016 158 Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H2 2016 159 Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Ltd, H2 2016 160 Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2016 161 Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene Inc, H2 2016 162 Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2016 163 Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2016 164 Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2016 165 Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2016 166 Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 167 Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2016 168 Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2016 169 Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2016 170 Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H2 2016 171 Multiple Myeloma (Kahler Disease) - Pipeline by Karus Therapeutics Ltd, H2 2016 172 Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 173 Multiple Myeloma (Kahler Disease) - Pipeline by Kesios Therapeutics Ltd, H2 2016 174 Multiple Myeloma (Kahler Disease) - Pipeline by Kite Pharma Inc, H2 2016 175 Multiple Myeloma (Kahler Disease) - Pipeline by LG Life Science LTD, H2 2016 176 Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2016 177 Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune LLC, H2 2016 178 Multiple Myeloma (Kahler Disease) - Pipeline by Medivation Inc, H2 2016 179 Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2016 180 Multiple Myeloma (Kahler Disease) - Pipeline by Mesoblast Ltd, H2 2016 181 Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 182 Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2016 183 Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2016 184 Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2016 185 Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2016 186 Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2016 187 Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2016 188 Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H2 2016 189 Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2016 190 Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2016 191 Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2016 192 Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2016 193 Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2016 194 Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc, H2 2016 195 Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2016 196 Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 197 Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International Inc, H2 2016 198 Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H2 2016 199 Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2016 200 Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2016 201 Multiple Myeloma (Kahler Disease) - Pipeline by Phylogica Ltd, H2 2016 202 Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd, H2 2016 203 Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2016 204 Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2016 205 Multiple Myeloma (Kahler Disease) - Pipeline by Quimatryx SL, H2 2016 206 Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2016 207 Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2016 208 Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2016 209 Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2016 210 Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Inc, H2 2016 211 Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H2 2016 212 Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2016 213 Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2016 214 Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 215 Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 216 Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2016 217 Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 218 Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2016 219 Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2016 220 Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 221 Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H2 2016 222 Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 223 Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2016 224 Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2016 225 Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2016 226 Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 227 Multiple Myeloma (Kahler Disease) - Pipeline by Theravectys SA, H2 2016 228 Multiple Myeloma (Kahler Disease) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 229 Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 230 Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2016 231 Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2016 232 Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2016 233 Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016 234 Multiple Myeloma (Kahler Disease) - Pipeline by Verastem Inc, H2 2016 235 Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H2 2016 236 Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H2 2016 237 Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2016 238 Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd, H2 2016 239 Assessment by Monotherapy Products, H2 2016 240 Assessment by Combination Products, H2 2016 241 Number of Products by Stage and Target, H2 2016 243 Number of Products by Stage and Mechanism of Action, H2 2016 266 Number of Products by Stage and Route of Administration, H2 2016 290 Number of Products by Stage and Molecule Type, H2 2016 292 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2016 1054 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..1), H2 2016 1055 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..2), H2 2016 1056 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..3), H2 2016 1057 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..4), H2 2016 1058 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..5), H2 2016 1059 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..6), H2 2016 1060 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..7), H2 2016 1061 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..8), H2 2016 1062 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..9), H2 2016 1063 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..10), H2 2016 1064 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..11), H2 2016 1065 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..12), H2 2016 1066 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..13), H2 2016 1067 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..14), H2 2016 1068 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..15), H2 2016 1069 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..16), H2 2016 1070 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..17), H2 2016 1071 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..18), H2 2016 1072 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..19), H2 2016 1073 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..20), H2 2016 1074 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..21), H2 2016 1075 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..22), H2 2016 1076 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..23), H2 2016 1077 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..24), H2 2016 1078 Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..25), H2 2016 1079 Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2016 1080 Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..1), H2 2016 1081 Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..2), H2 2016 1082 Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..3), H2 2016 1083 Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..4), H2 2016 1084
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
